Brent L Fogel1, Hane Lee2, Joshua L Deignan2, Samuel P Strom2, Sibel Kantarci2, Xizhe Wang1, Fabiola Quintero-Rivera2, Eric Vilain3, Wayne W Grody4, Susan Perlman1, Daniel H Geschwind5, Stanley F Nelson6. 1. Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles. 2. Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles3UCLA Clinical Genomics Center, David Geffen School of Medicine, University of California at Los Angeles. 3. UCLA Clinical Genomics Center, David Geffen School of Medicine, University of California at Los Angeles4Department of Human Genetics, David Geffen School of Medicine, University of California at Los Angeles5Department of Pediatrics, David Geffen School of. 4. Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles3UCLA Clinical Genomics Center, David Geffen School of Medicine, University of California at Los Angeles4Department of Human Genetics. 5. Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles4Department of Human Genetics, David Geffen School of Medicine, University of California at Los Angeles. 6. Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles2Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles3UCLA Clin.
Abstract
IMPORTANCE: Cerebellar ataxias are a diverse collection of neurologic disorders with causes ranging from common acquired etiologies to rare genetic conditions. Numerous genetic disorders have been associated with chronic progressive ataxia and this consequently presents a diagnostic challenge for the clinician regarding how to approach and prioritize genetic testing in patients with such clinically heterogeneous phenotypes. Additionally, while the value of genetic testing in early-onset and/or familial cases seems clear, many patients with ataxia present sporadically with adult onset of symptoms and the contribution of genetic variation to the phenotype of these patients has not yet been established. OBJECTIVE: To investigate the contribution of genetic disease in a population of patients with predominantly adult- and sporadic-onset cerebellar ataxia. DESIGN, SETTING, AND PARTICIPANTS: We examined a consecutive series of 76 patients presenting to a tertiary referral center for evaluation of chronic progressive cerebellar ataxia. MAIN OUTCOMES AND MEASURES: Next-generation exome sequencing coupled with comprehensive bioinformatic analysis, phenotypic analysis, and clinical correlation. RESULTS: We identified clinically relevant genetic information in more than 60% of patients studied (n = 46), including diagnostic pathogenic gene variants in 21% (n = 16), a notable yield given the diverse genetics and clinical heterogeneity of the cerebellar ataxias. CONCLUSIONS AND RELEVANCE: This study demonstrated that clinical exome sequencing in patients with adult-onset and sporadic presentations of ataxia is a high-yield test, providing a definitive diagnosis in more than one-fifth of patients and suggesting a potential diagnosis in more than one-third to guide additional phenotyping and diagnostic evaluation. Therefore, clinical exome sequencing is an appropriate consideration in the routine genetic evaluation of all patients presenting with chronic progressive cerebellar ataxia.
IMPORTANCE: Cerebellar ataxias are a diverse collection of neurologic disorders with causes ranging from common acquired etiologies to rare genetic conditions. Numerous genetic disorders have been associated with chronic progressive ataxia and this consequently presents a diagnostic challenge for the clinician regarding how to approach and prioritize genetic testing in patients with such clinically heterogeneous phenotypes. Additionally, while the value of genetic testing in early-onset and/or familial cases seems clear, many patients with ataxia present sporadically with adult onset of symptoms and the contribution of genetic variation to the phenotype of these patients has not yet been established. OBJECTIVE: To investigate the contribution of genetic disease in a population of patients with predominantly adult- and sporadic-onset cerebellar ataxia. DESIGN, SETTING, AND PARTICIPANTS: We examined a consecutive series of 76 patients presenting to a tertiary referral center for evaluation of chronic progressive cerebellar ataxia. MAIN OUTCOMES AND MEASURES: Next-generation exome sequencing coupled with comprehensive bioinformatic analysis, phenotypic analysis, and clinical correlation. RESULTS: We identified clinically relevant genetic information in more than 60% of patients studied (n = 46), including diagnostic pathogenic gene variants in 21% (n = 16), a notable yield given the diverse genetics and clinical heterogeneity of the cerebellar ataxias. CONCLUSIONS AND RELEVANCE: This study demonstrated that clinical exome sequencing in patients with adult-onset and sporadic presentations of ataxia is a high-yield test, providing a definitive diagnosis in more than one-fifth of patients and suggesting a potential diagnosis in more than one-third to guide additional phenotyping and diagnostic evaluation. Therefore, clinical exome sequencing is an appropriate consideration in the routine genetic evaluation of all patients presenting with chronic progressive cerebellar ataxia.
Authors: S T Sherry; M H Ward; M Kholodov; J Baker; L Phan; E M Smigielski; K Sirotkin Journal: Nucleic Acids Res Date: 2001-01-01 Impact factor: 16.971
Authors: Gregory M Cooper; Eric A Stone; George Asimenos; Eric D Green; Serafim Batzoglou; Arend Sidow Journal: Genome Res Date: 2005-06-17 Impact factor: 9.043
Authors: François Gros-Louis; Nicolas Dupré; Patrick Dion; Michael A Fox; Sandra Laurent; Steve Verreault; Joshua R Sanes; Jean-Pierre Bouchard; Guy A Rouleau Journal: Nat Genet Date: 2006-12-10 Impact factor: 38.330
Authors: Ivan A Adzhubei; Steffen Schmidt; Leonid Peshkin; Vasily E Ramensky; Anna Gerasimova; Peer Bork; Alexey S Kondrashov; Shamil R Sunyaev Journal: Nat Methods Date: 2010-04 Impact factor: 28.547
Authors: Anna Sailer; Sonja W Scholz; J Raphael Gibbs; Arianna Tucci; Janel O Johnson; Nicholas W Wood; Vincent Plagnol; Holger Hummerich; Jinhui Ding; Dena Hernandez; John Hardy; Howard J Federoff; Bryan J Traynor; Andrew B Singleton; Henry Houlden Journal: Neurology Date: 2012-06-06 Impact factor: 11.800
Authors: Sarah L Sawyer; Jeremy Schwartzentruber; Chandree L Beaulieu; David Dyment; Amanda Smith; Jodi Warman Chardon; Grace Yoon; Guy A Rouleau; Oksana Suchowersky; Victoria Siu; Lisa Murphy; Robert A Hegele; Christian R Marshall; Dennis E Bulman; Jacek Majewski; Mark Tarnopolsky; Kym M Boycott Journal: Hum Mutat Date: 2014-01 Impact factor: 4.878
Authors: Petya Bogdanova-Mihaylova; Neil Austin; Michael D Alexander; Lorraine Cassidy; Anne Early; Raymond P Murphy; Sinéad M Murphy; Richard A Walsh Journal: Mov Disord Clin Pract Date: 2016-07-18